A Single Center, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Tocilizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PACTO
- 27 Jan 2017 Planned End Date changed from 1 Dec 2019 to 26 Jan 2020.
- 27 Jan 2017 Planned primary completion date changed from 1 Dec 2018 to 26 Jan 2019.
- 27 Jan 2017 Status changed from not yet recruiting to recruiting.